Owens & Minor, Inc. is a global healthcare solutions company that incorporates product manufacturing, distribution support and innovative technology services to deliver significant and sustained value across the breadth of the industry – from acute care to patients in their home. Aligned to its Mission of Empowering Its Customers to Advance HealthcareTM, more than 15,000 global teammates serve over 4,000 healthcare industry customers. A vertically-integrated, predominantly Americas-based footprint enables Owens & Minor to reliably supply its self-manufactured surgical and PPE products. This seamless value chain integrates with a portfolio of products representing 1,200 branded suppliers. Operating continuously since 1882 from its headquarters in Richmond, Virginia, Owens & Minor has grown into a FORTUNE 500 company with operations located across North America, Asia, Europe and Latin America.

Company profile
Ticker
OMI
Exchange
Website
CEO
Edward Pesicka
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
O&M HOLDING INC, OWENS & MINOR INC
SEC CIK
Corporate docs
Subsidiaries
Owens & Minor Distribution, Inc. • Owens & Minor Medical, Inc. • Barista Acquisition I, LLC • Barista Acquisition II, LLC • O&M Halyard, Inc. • Byram Holdings • Byram Healthcare Centers, Inc. • Owens & Minor International • 500 Expressway Drive South LLC • Access Diabetic Supply, L.L.C. ...
IRS number
541701843
OMI stock data
News
Allina Health and Owens & Minor Expand Partnership and Announce New Strategic Collaboration, No Terms Disclosed
9 Aug 22
Baird Maintains Outperform on Owens & Minor, Lowers Price Target to $62
4 Aug 22
Credit Suisse Maintains Neutral on Owens & Minor, Lowers Price Target to $37
4 Aug 22
This Biotechnology Stock Jumped Over 360%; Here Are 106 Biggest Movers From Yesterday
4 Aug 22
Why Poseida Therapeutics Almost Doubled Today, Here Are 75 Stocks Moving In Wednesday's Mid-Day Session
3 Aug 22
Press releases
Allina Health and Owens & Minor Expand Partnership and Announce New Strategic Collaboration
9 Aug 22
Owens & Minor Reports Second Quarter 2022 Financial Results
3 Aug 22
David R. Myers of Owens & Minor Receives Prestigious Bellwether League Foundation Hall of Fame Recognition
1 Aug 22
Owens & Minor Announces Second Quarter 2022 Earnings Release Date
21 Jul 22
Owens & Minor Elects Carissa Rollins to Board of Directors
12 Jul 22
Analyst ratings and price targets
Current price
Average target
$49.50
Low target
$37.00
High target
$62.00
Baird
Maintains
$62.00
Credit Suisse
Maintains
$37.00
Calendar
3 Aug 22
13 Aug 22
31 Dec 22
Financial summary
Quarter (USD) | Jun 22 | Mar 22 | Dec 21 | Sep 21 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 21 | Dec 20 | Dec 19 | Dec 18 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 73.03M | 73.03M | 73.03M | 73.03M | 73.03M | 73.03M |
Cash burn (monthly) | 51.66M | (no burn) | (no burn) | (no burn) | (no burn) | (no burn) |
Cash used (since last report) | 75.28M | n/a | n/a | n/a | n/a | n/a |
Cash remaining | -2.25M | n/a | n/a | n/a | n/a | n/a |
Runway (months of cash) | -0.0 | n/a | n/a | n/a | n/a | n/a |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
15 Jul 22 | Robert J Henkel | Common Stock | Buy | Acquire P | No | Yes | 31.76 | 1,000 | 31.76K | 27,000 |
12 Jul 22 | Carissa Rollins | Common Stock | Grant | Acquire A | No | No | 0 | 4,490 | 0 | 4,490 |
11 Jul 22 | Tammy L Gomez | Common Stock | Grant | Acquire A | No | No | 0 | 15,904 | 0 | 15,904 |
Institutional ownership, Q1 2022
13F holders | Current |
---|---|
Total holders | 263 |
Opened positions | 34 |
Closed positions | 44 |
Increased positions | 87 |
Reduced positions | 102 |
13F shares | Current |
---|---|
Total value | 3.38B |
Total shares | 76.72M |
Total puts | 248.1K |
Total calls | 221.4K |
Total put/call ratio | 1.1 |
Largest owners | Shares | Value |
---|---|---|
BLK Blackrock | 11.9M | $523.7M |
FMR | 9.96M | $438.54M |
Vanguard | 8.07M | $355.18M |
Wellington Management | 7.55M | $332.48M |
Dimensional Fund Advisors | 3.31M | $145.65M |
STT State Street | 2.73M | $120.19M |
William Blair Investment Management | 2.63M | $115.94M |
Allspring Global Investments | 2.23M | $98.25M |
Brown Advisory | 1.55M | $68.14M |
Renaissance Technologies | 1.53M | $67.35M |
Financial report summary
?Risks
- Our operating income is dependent on certain significant domestic suppliers.
- An interruption in the ability of our business to manufacture products may have a material adverse effect on our business.
- An inability to obtain key components, raw materials or manufactured products from third parties may have a material adverse effect on our business.
- Our Global Products segment is exposed to price fluctuations of key commodities, which may negatively impact our results of operations.
- Our business and operations depend on the proper functioning of critical facilities, supply chain and distribution networks.
- Interruption of our supply chain could affect our ability to produce or distribute our products and could negatively impact our business and profitability.
- Our profitability and cash flow may vary based on the impacts of rising inflationary pressures.
- Our operations depend on the proper functioning of information systems, and our business or results of operations could be adversely affected if we experience a cyberattack or other systems breach or failure.
- Our ability to attract and retain talented and qualified teammates is critical to our success and competitiveness.
- We have concentration in and dependence on certain healthcare provider customers and Group Purchasing Organizations.
- We cannot assure you that the proposed Apria Acquisition will be completed.
- We may fail to realize the anticipated benefits of the Apria Acquisition or those benefits may take longer to realize than expected. We may also encounter significant difficulties in integrating the Apria business into our operations.
- We and the Apria business will be subject to business uncertainties while the Apria Acquisition is pending that could adversely affect our business and the Apria business.
- The pendency of the Apria Acquisition could adversely affect our business, financial results, and operations.
- Our results of operations may suffer upon the bankruptcy, insolvency, or other credit failure of a customer that has a substantial amount owed to us.
- We are subject to stringent regulatory and licensing requirements.
- We must obtain clearance or approval from the appropriate regulatory authorities prior to introducing a new product or a modification to an existing product. The regulatory clearance process may result in substantial costs, delays and limitations on the types and uses of products we can bring to market, any of which could have a material adverse effect on our business.
- Our business may be adversely affected if we are unable to adequately establish, maintain, protect and enforce our intellectual property and proprietary rights or prevent third parties from making unauthorized use of such rights.
- We may become subject to litigation brought by third parties claiming infringement, misappropriation or other violation by us of their intellectual property rights.
- We may incur product liability losses, litigation liability, product recalls, safety alerts or regulatory action associated with the products that we source, assemble, manufacture and sell which can be costly and disruptive to our business.
- Audits by tax authorities could result in additional tax payments for prior periods, and tax legislation could materially adversely affect our financial results and tax liabilities.
- We may not be able to generate sufficient cash to service our debt and other obligations.
- We may not be able to refinance, extend or repay our substantial indebtedness which would have a material adverse affect on our financial condition.
- Despite current indebtedness levels, we will incur substantially more debt to complete the acquisition of Apria, Inc. (Apria Acquisition) which could further exacerbate the risks described herein.
- Our variable rate indebtedness subjects us to interest rate risk, which could cause our indebtedness service obligations to increase significantly.
- Our credit facilities and our existing notes have restrictive covenants that could limit our financial flexibility.
- General economic conditions may adversely affect demand for our products and services.
- Changing conditions in the United States healthcare industry may impact our results of operations.
- Our continued success is substantially dependent on positive perceptions of our reputation.
- Our goodwill may become impaired, which would require us to record a significant charge to earnings in accordance with generally accepted accounting principles.
- We may be adversely affected by global climate change or by legal, regulatory or market responses to such change.
Management Discussion
- Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations
- related notes thereto, and management’s discussion and analysis of financial condition and results of operations included in our Annual Report on Form 10-K for the year ended December 31, 2021.
- Owens & Minor, Inc., along with its subsidiaries, (we, us, or our) is a leading global healthcare solutions company. To better reflect how we go to market as well as certain changes to the leadership team, organizational structure, budgeting and financial reporting processes, we have organized our business into two distinct segments: Products & Healthcare Services and Patient Direct. Products & Healthcare Services provides distribution, outsourced logistics and value-added services, and manufactures and sources medical surgical products through our production and kitting operations. Patient Direct expands our business along the continuum of care through delivery of disposable medical supplies sold directly to patients and home health agencies and is a leading provider of integrated home healthcare equipment and related services in the United States. Beginning with the quarter ended March 31, 2022, we now report financial results using this two segment structure and have recast prior year segment results on the same basis.
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. sophomore Avg
|
New words:
accrual, cancellable, commitment, computed, computing, created, entitled, excellence, implicit, inflation, leasehold, macroeconomic, method, Morgantown, noncancelable, noncancellable, point, prepaid, proportional, remitted, rental, shorter, site, Virginia, West
Removed:
board, charitable, decreased, defense, Department, European, force, granted, Human, life, national, partial, payment, recovery, reputation, shift, support, teammate, travel
Financial reports
Current reports
8-K
Owens & Minor Reports Second Quarter 2022 Financial Results
3 Aug 22
8-K
Owens & Minor Elects Carissa Rollins to Board of Directors
12 Jul 22
8-K
Owens & Minor Elects Rita Johnson-Mills and Terri Kline to Board of Directors
1 Jun 22
8-K
Regulation FD Disclosure
23 May 22
8-K
Regulation FD Disclosure
5 May 22
8-K
Owens & Minor Reports First Quarter 2022 Financial Results
3 May 22
8-K
Amendments to Articles of Incorporation or Bylaws
29 Apr 22
8-K
Regulation FD Disclosure
21 Apr 22
8-K
Index to Financial Statements
29 Mar 22
8-K
Owens & Minor Announces Upsize and Pricing of $600 Million of Senior Notes due 2030
23 Mar 22
Registration and prospectus
S-8
Registration of securities for employees
4 May 22
S-8 POS
Registration of securities for employees (post-effective amendment)
16 Dec 20
S-8
Registration of securities for employees
16 Dec 20
424B5
Prospectus supplement for primary offering
5 Oct 20
424B2
Prospectus for primary offering
29 Sep 20
424B3
Prospectus supplement
21 May 20
S-3
Shelf registration
7 May 20
S-8
Registration of securities for employees
7 May 20
S-8
Registration of securities for employees
10 May 19
S-8
Registration of securities for employees
9 May 18
Proxies
DEFA14A
Additional proxy soliciting materials
13 Apr 22
DEFA14A
Additional proxy soliciting materials
17 Mar 22
DEFA14A
Additional proxy soliciting materials
17 Mar 21
DEFA14A
Additional proxy soliciting materials
6 Apr 20
DEFA14A
Additional proxy soliciting materials
19 Mar 20
DEFA14A
Additional proxy soliciting materials
28 Mar 19
DEF 14A
Definitive proxy
28 Mar 19
Other
SD
Conflict minerals disclosure
26 May 22
SD
Conflict minerals disclosure
27 May 21
UPLOAD
Letter from SEC
17 Jun 20
SD
Conflict minerals disclosure
29 May 20
EFFECT
Notice of effectiveness
21 May 20
CORRESP
Correspondence with SEC
17 May 20
UPLOAD
Letter from SEC
8 Jan 20
CORRESP
Correspondence with SEC
16 Dec 19
UPLOAD
Letter from SEC
2 Dec 19
SD
Conflict minerals disclosure
23 May 19
Ownership
4
OWENS & MINOR / Robert J Henkel ownership change
15 Jul 22
4
OWENS & MINOR / Carissa Rollins ownership change
13 Jul 22
3
OWENS & MINOR / Carissa Rollins ownership change
12 Jul 22
4
OWENS & MINOR / Tammy L Gomez ownership change
12 Jul 22
3
OWENS & MINOR / Tammy L Gomez ownership change
12 Jul 22
4
OWENS & MINOR / Nicholas J Pace ownership change
5 Jul 22
4
OWENS & MINOR / Edward A Pesicka ownership change
5 Jul 22
4
OWENS & MINOR / Jeffrey T Jochims ownership change
5 Jul 22
4
OWENS & MINOR / MARK F MCGETTRICK ownership change
3 Jun 22
4
OWENS & MINOR / Robert J Henkel ownership change
3 Jun 22
Patents
Utility
Method and System for Manufacturing Facemasks in a Production Line
15 Jul 20
An automated system and method for the manufacture of facemasks from a web of a textile product in a production line is provided.
Utility
Method and System for Wrapping Ties in a Facemask Manufacturing Process
3 Jun 20
An automated system and method wrap the fastening ties around the body of a continuous stream of facemasks in a facemask production line.
Utility
Method and System for Wrapping Ties in a Facemask Manufacturing Process
27 May 20
An automated system and method wrap the fastening ties around the body of a continuous stream of facemasks in a facemask production line.
Transcripts
2022 Q2
Earnings call transcript
3 Aug 22
2022 Q1
Earnings call transcript
4 May 22
2021 Q4
Earnings call transcript
23 Feb 22
2021 Q3
Earnings call transcript
3 Nov 21
2021 Q2
Earnings call transcript
3 Aug 21
2021 Q1
Earnings call transcript
5 May 21
2020 Q4
Earnings call transcript
24 Feb 21
2020 Q3
Earnings call transcript
3 Nov 20
2020 Q2
Earnings call transcript
5 Aug 20
2020 Q1
Earnings call transcript
6 May 20
Reddit threads
Daily Discussion Thread - August 3rd, 2022
3 Aug 22
Daily Discussion Thread - August 2nd, 2022
2 Aug 22
Daily Discussion Thread - August 1st, 2022
1 Aug 22
Daily Discussion Thread - May 3rd, 2022
3 May 22
Daily Discussion Thread - May 2nd, 2022
2 May 22
Top 5 Value stocks right now?
11 Apr 22
Undervalued stocks. Name a few buy opportunities that most people are sleeping on right now.
15 Mar 22
Daily Discussion Thread - February 23rd, 2022
23 Feb 22
Daily Discussion Thread - February 22nd, 2022
22 Feb 22
Daily Discussion Thread - February 21st, 2022
21 Feb 22